Team:Paris Bettencourt/Project/Overview

From 2013.igem.org

(Difference between revisions)
 
(21 intermediate revisions not shown)
Line 2: Line 2:
{{:Team:Paris_Bettencourt/Menu}}
{{:Team:Paris_Bettencourt/Menu}}
<html>
<html>
 +
<div style="width:1100px;margin:0 auto;">
 +
<img src="https://static.igem.org/mediawiki/2013/3/3a/PB_logoParis.gif" width="122px" style="position:absolute;top:40px;right:30px;"/>
 +
</div>
 +
   <link href='http://fonts.googleapis.com/css?family=Great+Vibes' rel='stylesheet' type='text/css'>
   <link href='http://fonts.googleapis.com/css?family=Great+Vibes' rel='stylesheet' type='text/css'>
   <img src="https://static.igem.org/mediawiki/2013/d/da/PB_banneroverviewProjects.png"/>
   <img src="https://static.igem.org/mediawiki/2013/d/da/PB_banneroverviewProjects.png"/>
Line 25: Line 29:
     height:73px;
     height:73px;
     margin-bottom:15px;
     margin-bottom:15px;
-
     font-size:4em;
+
     font-size:2em;
     line-height:73px;
     line-height:73px;
     text-align:center;
     text-align:center;
 +
    font-weight:normal;
 +
  }
 +
  .factstile a:hover {
 +
    font-weight:bold;
 +
  }
 +
  .factstile a {
 +
    color: rgb(30,39,43);
   }
   }
   .leftparagraph {
   .leftparagraph {
Line 71: Line 82:
     <div class="abstractile">
     <div class="abstractile">
       <div class="leftparagraph">
       <div class="leftparagraph">
 +
<center><img src="https://static.igem.org/mediawiki/2013/d/d1/PB_overview2project.png" width="380"/></center>
       </div>
       </div>
       <div class="rightparagraph">
       <div class="rightparagraph">
       <p>
       <p>
-
  To defeat tuberculosis, we need new biotechnology. Our work will add 4 new tools to the anti-TB medical armamentarium. <b>Detect</b> - A CRISPR-based biosensor delivered by phage and sequence-specific for antibiotic resistance. <b>Target</b> - An <i>E. coli</i> model hosting an essential mycobacterial metabolic pathway that could simplify drug screening. <b>Infiltrate</b> - A E. coli strain capable of entering infected macrophages and lysing mycobacteria. <b>Sabotage</b> - A non-lytic phage that spreads horizontally in a bacterial population and expresses an siRNA to knock down antibiotic resistance.
+
  To defeat tuberculosis, we need new biotechnology. Our work adds 4 new tools to the anti-TB medical armamentarium. <b>Detect</b> - a CRISPR-based biosensor delivered by phage and sequence-specific for antibiotic resistance. <b>Target</b> - an <i>E. coli</i> model hosting an essential mycobacterial metabolic pathway that could simplify drug screening. <b>Infiltrate</b> - an <i>E. coli</i> strain capable of entering infected macrophages and lysing mycobacteria. <b>Sabotage</b> - a non-lytic phage that spreads horizontally in a bacterial population and expresses an siRNA to knock down antibiotic resistance.
       </p>  
       </p>  
       </div>
       </div>
Line 85: Line 97:
     </a>
     </a>
       <p>
       <p>
-
Diagnosing antibiotic resistance can improve treatment outcomes and slow the evolution of resistant strains. We propose a phage-delivered, CRISPR-based system that cuts specific DNA sequences and detects gene expression caused by DNA damage.
+
Diagnosing antibiotic resistance can improve and accelerate treatment. We propose a phage-delivered, CRISPR-based system that cuts specific DNA sequences and detects the presence of resistance genes due to the resulting DNA damage that is reported with a color output.
       </p>
       </p>
Line 96: Line 108:
       <p>  
       <p>  
-
<i>M. tuberculosis</i> grows slowly and is hard to study in the lab. We have transferred an essential mycobacterial metabolic pathway to <i>E. coli</i>, where is is easy to screen for targeted small-molecule inhibitors.
+
<i>M. tuberculosis</i> grows slowly and is hard to study in the lab. We have transferred an essential mycobacterial metabolic pathway to <i>E. coli</i>, where it is easy to screen for targeted small-molecule inhibitors.
       </p>
       </p>
Line 107: Line 119:
       <p>
       <p>
-
An effective TB therapy must reach mycobacteria inside lung macrophages. In this system, <i>E. coli</i> express lysteriolysin O (LLO) to enter the macrophage cytosol and Trehalose Dimycolate Hydrolase (TDMH) to degrade the pathogen's membrane.
+
An effective TB therapy must reach mycobacteria inside lung macrophages. In this system, <i>E. coli</i> express listeriolysin O (LLO) to enter the macrophage cytosol and Trehalose Dimycolate Hydrolase (TDMH) to degrade the pathogen's membrane.
       </p>
       </p>

Latest revision as of 00:27, 29 October 2013

FIGHT TUBERCULOSIS WITH MODERN WEAPONS

To defeat tuberculosis, we need new biotechnology. Our work adds 4 new tools to the anti-TB medical armamentarium. Detect - a CRISPR-based biosensor delivered by phage and sequence-specific for antibiotic resistance. Target - an E. coli model hosting an essential mycobacterial metabolic pathway that could simplify drug screening. Infiltrate - an E. coli strain capable of entering infected macrophages and lysing mycobacteria. Sabotage - a non-lytic phage that spreads horizontally in a bacterial population and expresses an siRNA to knock down antibiotic resistance.

Detect

Diagnosing antibiotic resistance can improve and accelerate treatment. We propose a phage-delivered, CRISPR-based system that cuts specific DNA sequences and detects the presence of resistance genes due to the resulting DNA damage that is reported with a color output.

Target

M. tuberculosis grows slowly and is hard to study in the lab. We have transferred an essential mycobacterial metabolic pathway to E. coli, where it is easy to screen for targeted small-molecule inhibitors.

Infiltrate

An effective TB therapy must reach mycobacteria inside lung macrophages. In this system, E. coli express listeriolysin O (LLO) to enter the macrophage cytosol and Trehalose Dimycolate Hydrolase (TDMH) to degrade the pathogen's membrane.

Sabotage

Totally drug-resistant TB (TDR-TB) is an established and growing problem. We have created a phage vector that delivers an siRNA capable of sabotaging drug resistance and restoring sensitivity. By reducing the fitness burden of our construct, we can promote its spread in a population.

Centre for Research and Interdisciplinarity (CRI)
Faculty of Medicine Cochin Port-Royal, South wing, 2nd floor
Paris Descartes University
24, rue du Faubourg Saint Jacques
75014 Paris, France
+33 1 44 41 25 22/25
team2013@igem-paris.org
Hit Counter by Digits
Copyright (c) 2013 igem.org. All rights reserved.